FITCH MONOCLONAL ANTIBODY

弗兰克W。芝加哥大学的惠誉单克隆抗体设施提供广泛的 专注于单克隆抗体的生成和生产的服务。发展至今 30多年前，杂交瘤技术的发展，使用单克隆抗体， 定义的特异性已成为快速发展的跨学科方法的重要工具， 生物医学技术和研究。因此，生成和正确操作 单克隆抗体对于特定项目的成功结果可能至关重要。以来 自1995年成立以来，该基金在与生产有关的所有领域都取得了广泛的经验， 单克隆抗体从开发独特的免疫方案到定制的ELISA筛查 的subclones。机构人员与研究人员及其工作人员密切合作， 单克隆抗体特别适合他们的需要。这种个人关注和互动， 加上适度的收费结构，使使用该基金成为一个合理的选择，以禁止 大多数商业供应商的费用。 在目前的资助期间，该基金通过生产抗体为UCCRC成员提供服务 对抗多种蛋白质研究人员利用抗体来评估诸如 肠上皮细胞恶性程度、各时相T细胞亚群的鉴定 免疫反应的水平，或细胞因子的水平，可以赋予抵抗肿瘤病毒。的 该工厂还利用生物反应器技术大规模生产高滴度抗体上清液， 抗体与FITC和生物素的偶联，以及ELISA的开发和优化。新 该设施的服务包括协助创建用于 研究者的实验室，定制融合以获得用于DNA分析的单克隆， 杂交瘤以获得和维持以最大水平产生抗体的细胞储备， 最近，协助解决纯化IgM抗体的困难任务。该设施的 敬业的工作人员和科学顾问致力于继续为癌症研究中心提供 会员和整个大学社区提供方便，高品质和具有成本效益的服务。

The Frank W. Fitch Monoclonal Antibody Facility at the University of Chicago provides a wide range of services focusing on the generation and production of monoclonal antibodies. Since the development of hybridoma technology more than thirty years ago, the use of monoclonal antibodies that have defined specificities has become an essential tool in the rapidly growing interdisciplinary approach to biomedical technology and research. Consequently, the generation and proper manipulation of monoclonal antibodies can be critical to the successful outcome of a particular project. Since its inception in 1995, the Facility has gained extensive experience in all areas related to the production of monoclonal antibodies from developing unique immunization schedules to customized ELISA screening of subclones. Facility personnel work closely with investigators and their staff in order to derive monoclonal antibodies specifically suited to their needs. This personal attention and interaction, together with a modest fee structure, makes using the Facility a reasonable option to the prohibitive charges of most commercial vendors. During the current funding period, the Facility has served UCCRC members by generating antibodies against a diverse array of proteins. Antibodies are utilized by investigators to assess such things as the degree of malignancy of intestinal epithelial cells, the identification of T cells subsets at various phases of the immune response, or the levels of cytokines which can confer resistance to tumor viruses. The Facility also offers large-scale production of high titer antibody supernatant using bioreactor technology, conjugation of antibodies to FITC and biotin, and the development and optimization of ELISAs. New services in the Facility include assistance in the creation of custom ELISAs to be used in the investigator's laboratory, customized fusions to obtain monoclonals for DNA analysis, subcloning of hybridomas to obtain and maintain stocks of cells that are producing antibody at maximum levels and, most recently, assistance in problem-solving the difficult task of purifying IgM antibodies. The Facility's dedicated staff and Scientific Advisor are committed to continuing to provide Cancer Research Center members and the entire University community with convenient, high-quality, and cost-effective services.